Annual Report 2023

Illustration showing blood cells affected by sickle cell.

BU Researchers Helped Develop the First FDA-Approved Gene Therapies to Treat Sickle Cell Disease

This year, the US Food and Drug Administration approved two groundbreaking treatments—both developed with the help of Boston University researchers—that alter genes to reduce a mutation in red blood cells associated with sickle cell disease.

Learn More

Groundbreaking Research

View All

Facts & Figures

View All
3,500 +

full-time faculty

7,697

publications in 2023

$ 579.5 M

total research awards in FY24

67 %

of federal funding is from the National Institutes of Health (FY23)

200 +

companies developing and selling products based on BU discoveries

Research Expenditures

Faculty Accolades

View All

Looking to the Future

View All
Kodiak Island

BU research is shaping tomorrow

Learn More

Information For...